Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.